Trial Profile
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Sunitinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 30 Jan 2017 Status changed from recruiting to withdrawn prior to enrolment as with recent advances in immunotherapy scientific question proved not significant
- 31 Mar 2015 New trial record